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Abstract:
The human immunodeficiency virus (HIV) infects the immune system that leads to immune deficiency. Acquired 
immunodeficiency syndrome (AIDS) is defined as the most advanced stages of HIV infection. It is defined by the 
occurrence of any of more than 20 opportunistic infections or HIV-related cancers. According WHO and 
UNAIDS estimation, 36.7 million people were living with HIV globally by the end of 2015. 2.1 million People 
became newly infected, and 1.1 million died of HIV-related causes at the same year. HIV-1 protease plays a 
vital role in the maturation of virus in order to produce the infectious viral particles. In this study, molecular 
docking was performed on various imidazole derivatives by Autodock 4.2 into active sites of HIV-1 protease 
(PDB ID: 4RVI).
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INTRODUCTION:
Drug designing is an inventive and integrated 
approach involving multiple steps based on the 
biological knowledge in order to design a new 
medication. The main aim of drug designing is to 
develop a drug in which it is having a high degree 
of chemotherapeutic index. To design, develop and 
commercialize a drug, it involves a tedious, time 
consuming and a high cost process. Taking into 
consideration all this factors, Computer-aided drug 
design (CADD) technique is being used now days 
in order to increase the efficiency in designing a 
drug. Using CADD technique, the three 
dimensional models of the drugs and their target 
site can be studied [1].
The rational drug design can be categorize into two 
broad groups. The first group is in which the 
desired properties for targets are developed from 
small molecules, where the functional roles of the 
cellular process and 3D structural information are 
already known. In another group, the development 
of small molecules with specified properties with 
the target maybe having the known or unknown 
structural function [2].
The frequently used method in Structural Based 
Drug Design is molecular docking. Molecular 
docking has the ability to predict the accuracy of 
the conformation small-molecule ligands within its 
appropriate target binding site. Using molecular 
docking, some tedious molecular events can be 
investigated such as performing experiment on 
ligand binding modes and the corresponding 
intermolecular interaction that stabilize the ligand 
receptor complex. Through molecular docking, one 
can quantitatively predict the binding energy based 
on the affinity of ligand-receptor complex binding. 
There are two steps involved in identification of 
binding conformations. The first step is exploration 
of a large conformational space representing 
various potential binding modes and the second 
step is the accurate prediction of the interaction 
energy associated with each of the predicted 
binding conformations. Cyclic process is being 
used by the molecular docking programs to 
perform such task, in which the ligand 
conformation is evaluated by a specific scoring 
function [3].
Acquired immunodeficiency syndrome (AIDS) is 
one of the ten deadliest diseases in the world as
concern with the global community. Human 
immunodeficiency virus (HIV) was found to be the 
causative agent in AIDS. HIV is a retrovirus from 
the genus Lentivirus. Commonly the retroviruses 
will be enveloped viruses. There are two identical, 
single stranded RNA molecules found in HIV as 
genetic material which is located in the center of it. 
Viral nucleocapsid (NC) protein, or which is 
known as p24 will be enclosing the genetic 
material. There are 7 internal proteins. 4 of the 
internal proteins are structural and the other 3 
proteins are enzymatic. The three enzymatic 
proteins are reverse transcriptase (RT), intergase 
(IN) and protease (PR). The three enzymatic 
proteins will be surrounded by the matrix (MA) 
protein or which is known as p17 and structural 
protein. The lipoprotein surface found on the HIV 
structure will be studded by envelope knobs which 
consist of glycoprotein gp120 and gp41.
Retrovirus become a HIV-1 by fusion between the 
attachment spikes like viral glycoprotein gp120 
which is the surface of envelope protein, gp41 
which is the Trans membrane protein and the host 
cell receptors which are the CD4, chemokine. The 
two viral RNA genomes and the viral enzymes (Pol 
proteins) reverse transcriptase (RT), intergase (IN) 
and protease (PR) are released by uncoating. 
Double stranded DNA is produced when reverse 
transcriptase copies the viral RNA. The new viral 
DNA will be transported in to the host cell nucleus, 
in which it is integrated into a host cell 
chromosome as a provirus by viral intergase (IN).  
When the host cell replicates, the provirus also may 
be replicated. The RNA for new retrovirus 
genomes and RNA that encodes the retrovirus 
capsid (CA), enzymes and envelope protein may be 
produced, from the transcription of the provirus. 
Viral proteases process the viral proteins and some 
of the viral proteins will be moved to the host 
plasma membrane. The mature retrovirus will leave 
the host cell, acquiring an envelope and attachment 
spikes as it buds out. The provirus which replicates 
at the latent state may produce new 
retroviruses.CCR5 and CXCR4 are the seven Trans 
membrane G protein-couples chemokine receptors 
which act as a core receptor for HIV-entry [4] 
Great efforts have been directed towards the 
development of antiretroviral therapies since the 
outbreak of AIDS. The antiretroviral therapies 
mainly target the HIV-1. One of the proteins which 
are mainly targeted is the HIV-1 Protease (PR). It is 
one of the important enzymes needed in order for 
assembly and maturation of the infectious virions 
HIV [5]. 
HIV-1 protease does play an important role in the 
maturation of viral in order to produce the virus 
particles which are infectious. There are at least 9 
distinct sites in which the protease cleaves the 
precursor of Gag and Gag-Pol polyproteins. From 
the cleavages, the structural protein matrix, capsid, 
nucleocaspid, spacer peptides p1,p2 and p6, 
functional enzymes reverse transcriptase, protease 
and integrase are being released. By modifying the 
role of the protease, it will help in deactivating the 
viral particles and it can aid in reducing the chances 
of infectivity. Due to this, inhibiting the HIV-1 
protease as a target in preventing HIV or AIDS has 
become common.  HIV-1 protease consists of an 
aspartic protease. The catalytic site of HIV-1 
protease is characterized as Asp-Thr-Gly sequence 
and it is applicable to all the aspartic protease [6]. 
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Imidazole is a planar five-membered ring system. It 
has three carbon and two nitrogen atom in position 
1 and 3. Glyoxaline was the first name given to 
imidazole [7]. The first synthesis of imidazole was 
done with glyoxal and ammonia. The amphoteric 
nature of imidazole allows it is susceptible to 
electophilic and nucleophilic attack and it function 
both as acid and base. Imidazole having 
characteristic such as highly stable to thermal, acid,
base, oxidation and reduction conditions. Imidazole 
is having extensive intramolecular hydrogen 
bonding [Delia Hernandez Romero et al., 2014]. 
Imidazole is highly soluble in water and other polar 
solvents. Since the hydrogen atom can be located 
on either side of each nitrogen, imidazole exists in 
two equivalent tautomeric forms. It is an aromatic 
compound due the presence of sextet of π-
electrons. It does also consist of a pair of electrons 
from the protonated nitrogen atom and one from 
each of the remaining four atoms of the ring [8].
Imidazole is having a unique position in 
heterocyclic chemistry since its derivatives are 
having a versatile property in in chemistry and 
pharmacology. The nitrogen containing 
heterocyclic ring of the imidazole possesses 
biological and pharmaceutical importance. Natural 
product such as purine, histamine, histidine and 
nucleic acid consist of imidazole ring. Since it is 
having the characteristic of being polar and 
ionisable aromatic compound, it helps in improving 
the pharmacokinetics characteristics of the lead 
molecules and it is used to optimize the solubility 
and bioavailability parameters of the poorly 
solouble lead molecules. The imidazole derivatives 
have a broad spectrum of biological activity such as 
antibacterial, anticancer, antitubercular, antifungal, 
analagesic and anti-HIV activities [9].
Imidazole derivatives could interfere with the HIV 
protein thus inhibit the replication of the retrovirus. 
Imidazole can easily bind with protein, due to these 
characteristics; they can bind to the reverse 
transcriptase site of the HIV-1 and inhibit the 
replication of the strain [10]. In this study, 
molecular docking was performed on various 
imidazole derivatives by Autodock 4.2 into active 
sites of HIV-1 protease (PDB ID: 4RVI).
MATERIALS AND METHODS:
Preparation of ligand
The ligands which are the nitroimidazole 
derivatives was chosen and designed. ChemSketch 
was used to draw the 2D structure of the ligands.
MarvinSketch was used to convert the 2D structure 
of the ligands into the 3D structures and it was later 
saved in pdb format. The pdb format of the ligands 
was viewed in USCF Chimera and the energy of 
the ligands was minimized using USCF Chimera.
Fig 1: Structure for Imidazole Derivatives
Table 1: List of Ligands
NO LIGANDS STRUCTURE IUPAC NAME
1 1A
N
N N
O
O
Cl
O
NH
CH3
1-(2-chloroethyl)-N-(3-ethylphenyl)-5-nitro-1H-
imidazole-2-carboxamide
2 2A
N
N N
O
O
Cl
O
NHCH3
1-(2-chloroethyl)-N-(4-methylcyclohexyl)-5-nitro-
1H-imidazole-2-carboxamide
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3 3A
N
N
NH
O
Cl
N
O
O
1-(2-chloroethyl)-N-(naphthalen-1-ylmethyl)-5-nitro-
1H-imidazole-2-carboxamide
4 4A
N
N N
O
O
Cl
O
NHCH3
1-(2-chloroethyl)-N-(4-methylphenyl)-5-nitro-1H-
imidazole-2-carboxamide
5 5A
N
N
N
O
O
Cl
O
NH
CH3 OCH 3
1-(2-chloroethyl)-N-(2-methoxy-5-methylphenyl)-5-
nitro-1H-imidazole-2-carboxamide
6 6A
N N
N O
O
Cl
ONH
OCH 3
CH3
1-(2-chloroethyl)-N-(2-methoxy-3-methylphenyl)-5-
nitro-1H-imidazole-2-carboxamide
7 7A
N N
N O
O
Cl
ONH
OCH 3
CH3
1-(2-chloroethyl)-N-(2-methoxy-4-methylphenyl)-5-
nitro-1H-imidazole-2-carboxamide
8 8A
N N
N O
O
Cl
ONHCH3
CH3
1-(2-chloroethyl)-N-(3,4-dimethylphenyl)-5-nitro-
1H-imidazole-2-carboxamide
9 9A
N N
N O
O
Cl
ONHCH3
CH3
1-(2-chloroethyl)-N-(3,5-dimethylphenyl)-5-nitro-
1H-imidazole-2-carboxamide
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10 10A
N
N
N
O
O
Cl
O
NH
CH3
CH3
1-(2-chloroethyl)-N-(2,5-dimethylphenyl)-5-nitro-
1H-imidazole-2-carboxamide
11 11A
N
N
Cl
O
NH
CH3
N
O
O
Cl
1-(2-chloroethyl)-N-(4-chloro-3-methylphenyl)-5-
nitro-1H-imidazole-2-carboxamide
12 12A
N
N
Cl
O
NH
Cl
CH3
N
O
O
1-(2-chloroethyl)-N-(2-chloro-5-methylphenyl)-5-
nitro-1H-imidazole-2-carboxamide
13 13A
N
N
Cl
O
NH
CH3
N
O
O
Cl
1-(2-chloroethyl)-N-(3-chloro-5-methylphenyl)-5-
nitro-1H-imidazole-2-carboxamide
14 14A
N
N
Cl
O
NH
CH3
N
O
OBr
N-(2-bromo-5-methylphenyl)-1-(2-chloroethyl)-5-
nitro-1H-imidazole-2-carboxamide
15 15A
N
N
Cl
O
NH
CH3
N
O
O
Br
N-(4-bromo-3-methylphenyl)-1-(2-chloroethyl)-5-
nitro-1H-imidazole-2-carboxamide
16 16A
N
N
Cl
O
NH
CH3
N
O
O
Br
N-(3-bromo-5-methylphenyl)-1-(2-chloroethyl)-5-
nitro-1H-imidazole-2-carboxamide
17 17A
N
N
NH
O
Cl
N
O
O
NH
O
N
N'-{[1-(2-chloroethyl)-5-nitro-1H-imidazol-2-
yl]carbonyl}pyridine-4-carbohydrazide
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18 18A
N
N
NH
O
Cl
N
O
O
Cl
1-(2-chloroethyl)-N-(3-chlorophenyl)-5-nitro-1H-
imidazole-2-carboxamide
Preparation of protein
The crystal structure of the target protein HIV-1 
protease (PDB ID: 4RVI) has been taken from the 
Protein Data Bank (PDB) database. The 
crystallized ligand was separated from the target 
protein by removing the heteroatoms in protein 
data bank data base and the energy of the protein 
was minimized by using USCF Chimera. This 
energy minimized protein was used in our study.
Fig 2: Ribbon Structure of 4RVI (Target 
Protein)
Molecular docking
In order to find the binding modes of ligands, 
docking of the ligands with HIV-1 protease was 
carried out using Autodock 4.2. The “Autodock 
tools” was used to prepare, run and analyze the 
docking stimulation. It requires a pre-calculated 
grid maps, one for each atom type present in the 
ligand being docked as it states the potential energy 
arising from the interaction with macromolecule. 
This grid must surround the region of interest 
which are the active site  in the macromolecule. 
In this study, the active site “Asp 25” was selected 
based on the amino acid residues of the co-
crystallized ligand bounded with HIV-1 protease 
(PDB ID: 4RVI). This would be considered as the 
best accurate active region as it is solved by 
experimental cystallographic data. 
Docking software Autodock 4.2 program supplied 
with Autogrid 4.0 and Autodock 4.0 was used to 
produce grid maps. Lamarkian Genetic Algorithm 
(LGA) was chosen to search for the best 
conformers. Maximum of 10 conformers was 
considered for each docking during the docking 
process.
RESULTS
TABLE 2: LIGANDS DOCKING RESULT
No Ligand Ligand 
Efficiency
Intermolecular 
Energy
Van Der 
Waals 
Dissolution 
Energy
Electrostatic 
Energy
Total 
Internal
energy
Unbound 
Energy
1 1A -022 -6.55 -6.77 0.22 -1.03 -1.03
2 2A -0.23 -6.28 -6.56 0.28 -1.07 -1.07
3 3A -0.2 -6.88 -7.42 0.54 -1.47 -1.47
4 4A -0.22 -6.12 -6.33 0.21 -0.96 -0.96
5 5A -0.23 -6.6 -6.76 0.16 -1.17 -1.17
6 6A -0.23 -6.55 -6.75 0.19 -1.22 -1.22
7 7A -0.2 -5.98 -6.18 0.21 -1.14 -1.14
8 8A -0.21 -6.21 -6.43 0.22 -1.0 -1.0
9 9A -0.23 -6.64 -6.95 0.31 -0.95 -0.95
10 10A -0.24 -6.67 -6.29 -0.38 -0.66 -0.66
11 11A -0.22 -6.37 -6.57 0.2 -1.06 -1.06
12 12A -0.24 -6.77 -7.12 0.34 -1.1 -1.1
13 13A -0.23 -6.6 -7.02 0.41 -0.93 -0.93
14 14A -0.25 -7.07 -7.23 0.16 -1.21 -1.21
15 15A -0.28 -7.62 -7.74 0.12 -1.08 -1.08
16 16A -0.22 -6.31 6.52 0.21 -1.04 -1.04
17 17A -0.16 -5.42 -5.77 0.35 -1.05 -1.05
18 18A -0.24 -6.46 -6.65 0.19 -1.1 -1.1
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Table 3: Interacting Residues, Hydrogen Bond and Its Distance, Binding Energy of Ligands and Their 
Inhibition Constant
No Ligands Interacting Residues Hydrogen Bond Hydrogen 
Bond 
Distance 
(Å)
Binding 
Energy 
(kJ/mol)
Inhibition 
Constant
1 1A ALA 28
ASP 29
GLY 48
GLY 49
ILE 50 A
ILE 50 B
ILE 84
VAL 32
pro: B: ILE 50: HN 2.205 -4.76 325.08µM
2 2A GLY 27
ILE 50 A
ILE 50 B
LEU 23
PRO 81
THR 82 A
THR 82 B
pro: B: ILE 50: HN 1.964 -4.79 307.5µM
3 3A ASP 25 A
ASP 25 B
GLY 27
GLY 49 
A
GLY 49 
B
ILE 50 A
ILE 50 B
ILE 84
LEU 23
THR 82
pro: A: ILE 50: HN 1.854 -5.09 185.01µM
4 4A ILE 50 A
ILE 50 B
THR 82 A
THR 82 B
pro: A: ILE 50: HN
pro: B: ILE 50: HN
2.226
2.087
-4.62 407.72µM
5 5A ALA 28
ASP 29
GLY 48
GLY 49 
A
GLY 49 B
ILE 50 A
ILE 50 B
pro: B: ASP 29: HN
pro: B: ILE 50: HN
2.15
2.008
-5.1 181.51µM
6 6A ASP 29
GLY 27
GLY 48
ILE 50
PRO 81
pro: B: ASP 29: HN 2.11 -5.06 194.58µM
7 7A ALA 28
GLY 27
ILE 50 A
ILE 50 B
ILE 84
pro: B: ILE 50: HN 2.205 -4.48 516.58µM
8 8A ALA 28
ASP 29
GLY 27
ILE 50
ILE 84
THR 82
pro: B: ASP 29: HN
pro: B: ILE 50: HN
2.167
2.152
-4.72 344.93µM
9 9A ILE 50 A
ILE 50 B
ILE 84
THR 80
THR 82
pro: A: ILE 50: HN
pro: B: ILE 50: HN
2.118
1.959
-5.15 168.52µM
10 10A ALA 28
ARG 8
ASP 29
GLY 27
GLY 48
GLY 49 
A
GLY 49 B
ILE 50 A
ILE 50 B
ILE 84
LEU 23
THR 82
pro: A: ILE 50: HN
pro: A: ILE 50: HN 
1.794
1.73
-5.18 160.17µM
11 11A ALA 28 
A
ALA 28 
B
ASP 29 A
ASP 29 B
GLY 27
ILE 50 A
ILE 50 B
ILE 84 A
ILE 84 B
VAL 32
pro: B: ASP 29: HN
pro: B: ILE 50: HN
2.115
2.03
-4.88 264.49µM
12 12A ILE 50 A
ILE 50 B
ILE 84
THR 80
THR 82
pro: A: ILE 50: HN 
pro: B: ILE 50: HN
2.054
1.858
-5.28 134.22µM
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13 13A GLY 49
ILE 50 A
ILE 50 B
LEU 23
PRO 81
THR 80
THR 82
pro: A: ILE 50: HN
pro: B: ILE 50: HN 
2.137
2.123
-5.11 178.93µM
14 14A ALA 28
ASP 29
GLY 48
GLY 49 
A
GLY 49 B
ILE 50 A
ILE 50 B
pro: B: ASP 29: HN
pro: B: ILE 50: HN
pro: A: ILE 50: HN
2.166
2.089
2.145
-5.58 81.47µM
15 15A ALA 28
ASP 25 A
ASP 25 B
ASP 29
ASP 30
GLY 27
GLY 48
GLY 49 A
GLY 49 B
ILE 50 A
ILE 50 B
ILE 84
pro: A: ASP 29: HN 1.901 -6.12 32.41µM
16 16A ILE 50 A
ILE 50 B
ILE 84
PRO 81
pro: B: ILE 50:HN 1.834 -4.82 292.4µM
17 17A ALA 28 
A
ALA 28 
B
ASP 29 A
ASP 29 B
GLY 27
ILE 50
ILE 84 A
ILE 84 B
VAL 32
pro: B: ASP 29:HN 1.93 -3.63 2.19mM
18 18A ALA 28
ASP 29
GLY 48
GLY 49
ILE 50 A
ILE 50 B
pro: A: ILE 50: HN
pro: B: ILE 50: HN
2.183
1.96
-4.97 226.6µM
Fig 3: Interacting Residues of Ligand 14A with HIV-1 Protease
Fig 4: Surface View of Ligand 14A complexes with HIV-1 Protease
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Ligand 14A was docked with HIV-1 Protease. The 
docking result shows that the binding energy of 
ligand 14A with HIV-1 protease to be -5.58 kJ/mol. 
The ligand efficiency is found to be -0.25, and the 
Van der Waals dissolution energy is -7.23. The 
intermolecular energy of the ligand shows -7.07 
with a total energy of -1.21. The inhibition constant 
was found to be 81.47 µM. There are seven Van 
der Waals interacting residues formed from 
docking result of Ligand 14A with HIV-1 protease; 
it includes ALA 28, ASP 29, GLY 48, GLY 49 A, 
GLY 49 B, ILE 50 A and ILE 50 B. Ligand 14A
exhibited 3 hydrogen bonds. The first hydrogen 
was found to be interacting with amino acid ASP 
29.  The hydrogen bond is found to be formed 
between amine functional group of the HIV-1 
protease and “O” atom in ligand with a bond 
distance of 2.166 Å. The other two hydrogen bonds 
were found to be interacting with amino acid ILE 
50 in the binding region. The hydrogen bonds are 
found to be formed between amine functional 
group of the HIV-1 protease and “O” atom in 
ligand with the bond distance of 2.089 Å and 2.145 
Å, respectively.
Fig 5: Interacting Residues of Ligand 12A with HIV-1 Protease
Fig 6: Surface View of Ligand 12A complexed with HIV-1 Protease
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Ligand 12A was docked with HIV-1 Protease. The 
docking result shows that the binding energy of 
ligand 12A with HIV-1 protease to be -5.28 kJ/mol. 
The ligand efficiency is found to be -0.24 and the 
Van der Waals dissolution energy is -7.12. The 
intermolecular energy of the ligand shows -6.77 
with a total energy of -1.1. The inhibition constant 
was found to be 134.22 µM. There are five Van der 
Waals interacting residues formed from docking 
result of Ligand 12A with HIV-1 protease, which
includes ILE 50 A, ILE 50 B, ILE 84, THR 80 and 
THR 82. Ligand 12A exhibited 2 hydrogen bonds.  
Both the hydrogen bond was found to be 
interacting with amino acid ILE 50 in the binding 
region. The hydrogen bonds are found to be formed 
between amine functional group of the HIV-1 
Protease and “O” atom in ligand with the bond 
distance of 1.858 Å and 2.054 Å, respectively. 
Fig 7: Interacting Residues of Ligand 10A with HIV-1 Protease
Fig 8: Surface View of Ligand 10Acomplexed with HIV-1 Protease
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Ligand 10A was docked with HIV-1 Protease. The 
docking result shows that the binding energy of 
ligand 10A with HIV-1 protease to be -5.18 kJ/mol. 
The ligand efficiency is found to be -0.24 and the 
Van der Waals dissolution energy is -6.29. The 
intermolecular energy of the ligand shows -6.67 
with a total energy of -0.66. The inhibition constant 
was found to be 160.17 µM. There are 12 Van der 
Waals interacting residues formed from docking 
result of Ligand 10A with HIV-1 protease, it 
includes ALA 28, ARG 8, ASP 29, GLY 27, GLY 
48, GLY 49 A, GLY 49 B, ILE 50 A, ILE 50 B, 
ILE 84, LEU 23 and THR 82 . Ligand 10A 
exhibited 2 hydrogen bonds. Both the hydrogen 
bond was found to be interacting with amino acid 
ILE 50 in the active site. Both hydrogen bonds are 
found to be formed between amine functional 
group of the HIV-1 Protease and oxygen in ligand 
with bond distance of 1.794 Å and 1.73 Å, 
respectively.
Fig 9: Interacting Residues of Ligand 13A with HIV-1 Protease
Fig 10: Surface View of Ligand 13Acomplexed with HIV-1 Protease
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Ligand 13A was docked with HIV-1 Protease. The 
docking result shows that the binding energy of 
ligand 13A with HIV-1 protease to be -5.11 kJ/mol. 
The ligand efficiency is found to be -0.23 and the 
Van der Waals dissolution energy is -7.02. The 
intermolecular energy of the ligand shows -6.6 with 
a total energy of -0.93. The inhibition constant was 
found to be 178.93 µM. There are 7 Van der Waals 
interacting residues formed from docking result of 
Ligand 13A with HIV-1 protease; it includes GLY 
49, ILE 50 A, ILE 50 B, LEU 23, PRO 81, THR 80 
and THR 82. Ligand 13A exhibited 2 hydrogen 
bonds.  Both the hydrogen bonds are found to be 
interacted with amino acid “ILE 50” in the binding 
region. The hydrogen bonds are found to be formed 
between amine functional group of the HIV-1 
Protease and “O” atom in ligand with the bond 
distance of 2.123 Å and 2.137 Å, respectively.
Fig 11: Interacting Residues of Ligand 15A with HIV-1 Protease
Fig 12: Surface View of Ligand 15Acomplexed with HIV-1 Protease
Ligand 15A was docked with HIV-1 Protease. The docking result shows that the binding energy of 
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ligand 15A with HIV-1 protease to be -6.12 kJ/mol. 
The ligand efficiency is found to be -0.28 and the 
Van der Waals dissolution energy is -7.74. The 
intermolecular energy of the ligand shows -7.62 
with a total energy of -1.08. The inhibition constant 
was found to be 32.41 µM. There are twelve Van 
der Waals interacting residues formed from 
docking result of Ligand 15A with HIV-1 protease, 
which includes ALA 28, ASP 25 A, ASP 25 B, 
ASP 29, ASP 30, GLY 27, GLY 48, GLY 49 A, 
GLY 49 B, ILE 50 A, ILE 50 B and ILE 84. 
Ligand 15A exhibits single hydrogen bond. The 
hydrogen is found to be interacted with amino acid 
“ASP 29”.  The hydrogen bond is found to be 
formed between amine functional group of the 
HIV-1 Protease and “O” atom in ligand with a
bond distance of 1.901 Å. 
DISCUSSION:
In the current study eighteen nitro-imidazole 
derivatives was chosen as the ligand, and the 
docking study was performed with HIV-1 Protease 
protein as a target receptor in this study. It was
done in order to identify the potential leads of HIV-
1 protease inhibitor based on the analysis of good 
binding energy, formation of hydrogen bonds,
distances of hydrogen bonds and the Van Der 
Waals interacting residues of ligand with docked 
protein. AutoDock 4.2 docking program with 
Lamarckian genetic algorithm was used to achieve 
the aim of this study. The HIV-1 Protease protein 
was extracted from the Protein Data Bank (PDB 
ID: 4RVI)
Out of the 18 compounds, 5 compounds show the 
highest binding energy. Ligand 15A and 14A
exhibit the maximum binding energy which are 
found to be -6.12 kJ/mol with ligand efficiency of -
0.28 and -5.58 kJ/mol with ligand efficiency of -
0.25 respectively. Maximum number of the ligand 
which was docked show the existence of hydrogen 
bonding with the amino acid residues ASP29 and 
ILE50. There were 3 hydrogen bonds formed from 
ligand 15A and it was found to be formed with 2 
residues, ASP29 and ILE50 of HIV-1 Protease 
protein.
CONCLUSION:
Molecular docking is one of the safest and easiest 
tools used in order to investigate the property of the 
molecules using a three-dimensional structure. In 
this study, molecular docking was conducted in a 
series of selected imidazole derivatives with HIV-1 
protease (PDB ID: 4RVI). All the selected 
imidazole derivatives show a good binding energy 
and also a good inhibition constant. This study 
provides us the theoretical framework to rationally 
design nitro-imidazole derivatives as HIV-1 
protease inhibitors.
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